SB202190 (FHPI)

Catalog No.S1077

SB202190 (FHPI) Chemical Structure

Molecular Weight(MW): 331.34

SB202190 (FHPI) is a potent p38 MAPK inhibitor targeting p38α/β with IC50 of 50 nM/100 nM in cell-free assays, sometimes used instead of SB 203580 to investigate potential roles for SAPK2a/p38 in vivo.

Size Price Stock Quantity  
In DMSO USD 134 In stock
USD 147 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • C, Jurkat cells with SB202190 at 1, 5, and 10 μM were tested, and a decreased SRP72 expression was found when using at 10 μM (lanes 8 and 9). D, results were analyzed and RUA illustrated, finding significant results at 10 μM at 240 versus 0 and 120 versus 0 min (p<0.05).

     

     

    J Biol Chem 2010 285, 32824–32833. SB202190 (FHPI) purchased from Selleck.

    C, effect of SB202190 (1, 5, and 10 μM) on SRP72 phosphorylation was tested. A decreased intensity of SRP72 expression when used at 1 μM (240 min) and 5 and 10 μM (120 and 240 min) was found. D, RUA illustrated obtaining significant results at concentration 5 and 10 μM at 120 versus 0 and 240 versus 0 min. * indicates p<0.05.

     

     

    J Biol Chem 2010 285, 32824–32833. SB202190 (FHPI) purchased from Selleck.

  • We used real time RT-PCR to investigate the effects of SB202190 on SRP72 mRNA expression. All the samples were treated under the same experimental conditions used in protein tests done by WB, and phosphorylation was measured indirectly by IP-WB. The results did not show significant changes on the mRNA expression of SRP72 after the treatment with these inhibitors.

     

     

    J Biol Chem 2010 285, 32824–32833. SB202190 (FHPI) purchased from Selleck.

Purity & Quality Control

Choose Selective p38 MAPK Inhibitors

Biological Activity

Description SB202190 (FHPI) is a potent p38 MAPK inhibitor targeting p38α/β with IC50 of 50 nM/100 nM in cell-free assays, sometimes used instead of SB 203580 to investigate potential roles for SAPK2a/p38 in vivo.
Targets
p38α [1]
(Cell-free assay)
p38β [1]
(Cell-free assay)
50 nM 100 nM
In vitro

SB 202190 significantly inhibits both basal and anti-Fas antibody-induced MAPKAPK 2 activity in a dose-dependent manner. SB202190 by itself is sufficient to induce cell death in Jurkat and HeLa cells through activation of CPP32-like caspases, which can be blocked by expression of bcl-2. SB202190-induced apoptosis is attenuated by p38β but augmented by p38α. [2] SB 202190 strongly inhibits UVB induced COX-2 protein expression in HaCaT cells, and markedly inhibits UVB induced cox-2 mRNA. [3] SB 202190 treatment inhibits the expression of albumin-induced proinflammatory (monocyte chemoattractant protein-1) and transforming growth factor (TGF)-beta1-induced profibrotic (procollagen-Ialpha1) genes over 50% in renal tubular cells (normal rat kidney-52E). [4] SB 202190 treatment induces phosphorylation of JNK in a dose- and time- dependent manner in A549 cells, induces phosphorylation of ATF-2 transcription factor, and increases AP-1 DNA binding. [6] SB 202190 treatment enhances the growth of THP-1 and MV4-11 cells. SB 202190 increases the phosphorylation of c-Raf and ERK, suggesting that Ras-Raf-MEK-mitogen-activated protein kinase (MAPK) pathway activation is involved in the leukemia cell growth induced by SB 202190. [7]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HCT-116 NXvNOoxuTnWwY4Tpc44hSXO|YYm= NUflVG83OjVizszN NIPBe5c{OCCvaX6= M4HRc2ROW00EoB?= MmW4ZZR1\W63YYTld{B1cGVibWLORUBidmRicILveIVqdiCneIDy[ZN{cW:wIH;mJIhDTC1{IHnuJJJme3CxboPpeoUhfG9iRFG= MoPrNlYzOjN{NUG=
MDA-MB-231 M3XhfmZ2dmO2aX;uJGF{e2G7 M3PZWFIh|ryP M1jWUVI1KGh? NHrzWmNt\XO|ZX7ld{BES0x{IHnu[JVkfGmxbjDifUBVVkcQsR?= M2rGZlI3OTByOES4
rBMSCs MlruSpVv[3Srb36gRZN{[Xl? MUmxNEDPxE1? NHvsTFIzNjViaB?= NFe3[lhl\XC{ZYPz[ZMhfGinIIDoc5NxcG:{eXzheIlwdiCxZjDFVmsh[W6mIICzPC=> M4rKXFI3ODV|Mk[2
MG63 Mkf0SpVv[3Srb36gRZN{[Xl? M4jo[FExNzJyL{OwJO69VQ>? NGfKXZczPCCq M17yT5Nq\26rZnnjZY51dHliZHXjdoVie2W|IITo[UBt\X[nbDDv[kBxcG:|cHjvdplt[XSnZDDwN|ghcW6mdXPl[EBjgSCFZFPsNkBqdiCjIHPvcoNmdnS{YYTpc44hNWSncHXu[IVvfCCvYX7u[ZI> MX2yOVk6QDNzMh?=
MG63 MWrBdI9xfG:|aYOgRZN{[Xl? NUHkbYJIOTBxMkCvN|Ah|ryP NELzco4zPCCq M2Tx[pNq\26rZnnjZY51dHliZHXjdoVie2WmIITo[UBieG:ydH;zbZMhemG2ZTDv[kBOTzZ|IHnu[JVk\WRiYomgR4REdDJ? M{\UUlI2QTl6M{Gy
HTSMCs M1rXXmZ2dmO2aX;uJGF{e2G7 MWmwMlEwOS9zMDFOwG0> MUSxJIg> MVrpcohq[mm2ZXSgR29TVS1{LXnu[JVk\WRiSF:tNUBxem:2ZXnuJIxmfmWuczDhcoQhdVKQQTDlfJBz\XO|aX;u M1;1cVI2QTJzNE[0
MIA PaCa-2 MnfuSpVv[3Srb36gRZN{[Xl? MUiyNOKh|ryP MUSyOEBp NHr6[Wdz\WS3Y3XkJIxi[3SjdHWgZYNkfW23bHH0bY9vKGmwIHPvcYJqdmG2aX;uJJdqfGhiYn;0bEAzNUSJIHHu[EBFNWGubH;z[eKh NHexU|kzPTh6OES4PS=>
MIA PaCa-2 NGfWbmhHfW6ldHnvckBCe3OjeR?= MmXNNlDDqM7:TR?= MmLhNlQhcA>? M2f0VZJme3WudIOgbY4h[SCvb3Tld5QhcW6qaXLpeIlwdiCxZjDITWYuOc7zIIDyc5RmcW5iYXPjeY12dGG2aX;u Mn[2NlU5QDh2OEm=
BxPC-3 NIXSV29HfW6ldHnvckBCe3OjeR?= MVyyNOKh|ryP NX:xVnhTOjRiaB?= MYXy[ZN2dHS|IHnuJIEhdW:mZYP0JIlvcGmkaYTpc44hd2ZiSFnGMVHPuSCycn;0[YlvKGGlY4XteYxifGmxbh?= MWiyOVg5QDR6OR?=
AsPC-1 MX;GeY5kfGmxbjDBd5NigQ>? MXyyNOKh|ryP MWOyOEBp MX;y[ZN2dHS|IHnuJIEhdW:mZYP0JIlvcGmkaYTpc44hd2ZiSFnGMVHPuSCycn;0[YlvKGGlY4XteYxifGmxbh?= MlK4NlU5QDh2OEm=
MIA PaCa-2 NFvFOYVHfW6ldHnvckBCe3OjeR?= M3;WWlIxyqEQvF2= NYD1dmprOjRiaB?= MWflcohidmOnczDjcIVifmGpZTDv[kBRSVKSIIfo[Y4h[2:vYnnu[YQhf2m2aDDncJVkd3OnIHHuZYxw\3N? MVOyOVg5QDR6OR?=
MIA PaCa-2 NWnodlZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDDPZUzOMLizszN NE\JbIIzKGh? MYfz[Y5{cXSrenXzJINmdGxibHnu[ZMhfG9idILlZZRu\W62IIfpeIghOi2GRzDhcoQhTC2jbHzvd4U> M37i[|I2QDh6NEi5
BxPC-3 M1LZOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1Xkb|IxyqEQvF2= NXTzeHh{OiCq MVvz[Y5{cXSrenXzJINmdGxibHnu[ZMhfG9idILlZZRu\W62IIfpeIghOi2GRzDhcoQhTC2jbHzvd4U> MYiyOVg5QDR6OR?=
AsPC-1 NWrjToRRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVuycYRZOjEEoN88US=> MkLZNkBp M3X3PJNmdnOrdHn6[ZMh[2WubDDsbY5meyC2bzD0doVifG2nboSge4l1cCB{LVTHJIFv\CCGLXHscI9{\Q>? MnniNlU5QDh2OEm=
HEY Ml\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7xNlDDqM7:TR?= NFmzelIzKGh? NGHWNGN{\W6|aYTpfoV{KGOnbHygcIlv\XNidH:geJJm[XSvZX70JJdqfGhiMj3ES{BidmRiRD3hcIxwe2V? NHnwR2EzPTh6OES4PS=>
OVCAR-3 M1TNc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHn[48zOMLizszN M1fBVVIhcA>? NVLIXIlLe2Wwc3n0bZpmeyClZXzsJIxqdmW|IITvJJRz\WG2bXXueEB4cXSqIEKtSGch[W6mIFStZYxtd3On NH7TcHMzPTh6OES4PS=>
SK-OV-3 NVnCO4l2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYWyNOKh|ryP NF\GS3IzKGh? M{X4UJNmdnOrdHn6[ZMh[2WubDDsbY5meyC2bzD0doVifG2nboSge4l1cCB{LVTHJIFv\CCGLXHscI9{\Q>? NIPZUFQzPTh6OES4PS=>
MH7A  Mlr3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFT6cXEzPCCq MnLadoVqdm[xcnPld{B1cGViaX7obYJqfG:{eTDl[oZm[3S|IH;mJHhCVg>? NFjhdmMzPTh4Mkm2Oi=>
MH7A  NIm2Z5VCeG:ydH;zbZMhSXO|YYm= NFz4bXMzPSEQvF2= NF7aRZczPCCq Ml3LdoV3\XK|ZYOgZ4VtdCCleXPs[UBienKnc4SgbY5lfWOnZDDifUBZSU5iYX7kJINifXOnZDDhdI9xfG:|aYOgc4Yh[2WubIOgeoliKGGldHn2ZZRqd25ib3[gTm5M NUT5fZNCOjV6NkK5OlY>
SCC25 MnrySpVv[3Srb36gRZN{[Xl? MkjXNlAh|ryP M3jGc|I1KGh? Ml:xbY5kemWjc3XzJIF2fG:yaHHnfUBt\X[nbB?= NGfWRZkzPTh|NESwNC=>
HaCaT  NXjSb2JsTnWwY4Tpc44hSXO|YYm= NULpTm5xPSEEtV2= NVv6S5p2OjRiaB?= NXP6NVdbcW6qaXLpeJMhUU[QLd8zMYlv\HWlZXSgR2NNOjJicILv[JVkfGmxbjDs[ZZmdHN? MWeyOVg{PDN3Mx?=
HaCaT  MULGeY5kfGmxbjDBd5NigQ>? M3\OcFUhyrWP MX:yOEBp NGDiXGNqdmirYnn0d{BKTk5vzsGtbY5lfWOnZDDDR2wzOiCycn;keYN1cW:wIHzleoVtew>? NGezd4szPTh|NEO1Ny=>
HPAEpiCs  MoXpSpVv[3Srb36gRZN{[Xl? MlTjNU8{NzFyIN88US=> Moj2NUBp MWXy[YR2[2W|IGOxVE1qdmS3Y3XkJGlESU1vMTDwdo91\WmwIHHu[EBuWk6DIHX4dJJme3Orb36gZY5lKHC{b33veIVzKGGldHn2bZR6 NETXT5ozPTd|NEmwNC=>
HPAEpiCs M{L1NWZ2dmO2aX;uJGF{e2G7 MUCxM|MwOTBizszN Mm[2NUBp MmjIbY5pcWKrdIOgV|FRNXO2aX31cIF1\WRiQXv0JJBpd3OyaH;yfYxifGmxbjCgxsA> NFL0fogzPTd|NEmwNC=>
HPAEpiCs M3\HOmZ2dmO2aX;uJGF{e2G7 M1zhXFEwOy9zMDFOwG0> M3[1[lEhcA>? NWHEOJFbcW6qaXLpeJMhWzGSIITpcYUu\GWyZX7k[Y51dHlic4TpcZVt[XSnZDDjMWp2diCyaH;zdIhwenmuYYTpc44> NIPhRnQzPTd|NEmwNC=>
K562 MYDGeY5kfGmxbjDBd5NigQ>? MVqxNOKh|ryP MkXINeKhcA>? M{W1WGROW09? NVPBXm5qcW6qaXLpeJMheXWrbnHjdolv\S2rbnT1Z4VlKHB|ODDNRXBMKHCqb4PwbI9zgWyjdHnvci=> M2q0OVI2Pjh2MESz
PANC-1 NWTu[YIyTnWwY4Tpc44hSXO|YYm= MUixNEDPxE1? M3XrWlEhcA>? M1jn[YVvcGGwY3XzJJRp\SCjdYTvdIhi\2mlIHXm[oVkfMLi NHWyWGwzPTZ|MkKyNi=>
BxPC-3 NFfJVYNHfW6ldHnvckBCe3OjeR?= Mm\5NVAh|ryP NEG5fHcyKGh? M4WwVIVvcGGwY3XzJJRp\SCjdYTvdIhi\2mlIHXm[oVkfMLi M2TWblI2PjN{MkKy
K562  Ml3uSpVv[3Srb36gRZN{[Xl? NY\1bWxKOC5{NT2xJO69VQ>? M{HSdVI1KGh? M1TFUpN2eHC{ZYPz[ZMhemW|dnXyZZRzd2xvaX7keYNm\CCKMlHYJJBpd3OyaH;yfYxifGmxbh?= MkO4NlU3OTl|OUK=
THP-1 NFjI[mFHfW6ldHnvckBCe3OjeR?= NHvETIc2KML3TR?= NV7YNGd1OiCq NYLDeXp2e2mpbnnmbYNidnSueTDheJRmdnWjdHXzJJNm[3KndHnvckBw\iCLTD2x{tEhcW6mdXPl[EBjgSB{N1;IR4hwdCCybIXzJGZUVC1zwrC= MWOyOVU6QDZ4MR?=
WB M1\MfmZ2dmO2aX;uJGF{e2G7 NF7J[XkzOOLCid88UeKh MVyzNQKBkW2rbh?= MWfk[YNz\WG|ZYOgeIhmKEySUz2gc5IhVFSDLXnu[JVk\WRiSVytOkBidmRiVF7GMe6yyqCycn;keYN1cW:w M1Pj[lI2PTNyNkiy
RAW 264.7 M2LxeGZ2dmO2aX;uJGF{e2G7 NV;3VG53OTEEoN88US=> NWSy[IxTOzEkgJntbY4> NYjnb4x{cW6mdXPld{BkcGG{YXP0[ZJqe3SrYzD2ZYN2d2yjdHnvckBw\iCRQ4RCpC=> M4LITlI2PDZzM{m5
RAW 264.7 M3S3emZ2dmO2aX;uJGF{e2G7 MWqxNOKh|ryP NU\IW|FYOzEkgJntbY4> MWfheJRmdnWjdHXzJJRp\SCnZn\lZ5R{KG:oIF;QS{BwdiCxc4Tlc4Nt[XO2IILleJJi[3Srb36= NYTJNZFUOjV2NkGzPVk>
HaCaT  MUXGeY5kfGmxbjDBd5NigQ>? NVzubI4yPDEEoN88US=> MlqyN{0zPCCq M4rubGROW09? M1XWUJJm\HWlZYOgeIhmKGGlY4XteYxifGmxbjDv[kBbVy1z NUfNN5Q{OjV2M{W0PFU>
H9c2 MnKxSpVv[3Srb36gRZN{[Xl? M4\yclUxyqEQvF5CpC=> MnO5NVIhcA>? MofzdoVlfWOnczDMSGghemWuZXHz[UBidmRiTV3QJIxwe3N? NH3DUoozPTJ2NUixPC=>
HSCs NUL6dm9PSXCxcITvd4l{KEG|c3H5 NXPJVVF5OjVizszN MUSyOOKhcA>? MmHTd4lodmmoaXPhcpRtgSCjdITlcpVifGW|IGTHMYlv\HWlZXSgZYN1cX[jdHXkJGhUS3NiYYDvdJRwe2m| M4\DdFI1QTZzOUWw
THP-1 NWXlPFFLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXi3U5ZmPzJiaB?= NUXTe3dLTE2VTx?= M3W1fGlEPTB;ND63{txO M{DCZVI1QDF3MEi3
MDDCs NVK3[2pZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmr3O|IhcA>? NUPGVoVxTE2VTx?= M3L1emlEPTB{LkhOwG0> MkXhNlQ5OTVyOEe=
MDDCs MW\GeY5kfGmxbjDBd5NigQ>? MnHNNE0yPSEQvF2= NGDmTIs1QCCq NXnPU2h4TE2VTx?= Morvd5VxeHKnc4Pld{BKTk5vzsGgZY5lKEmSLUGwJJBzd2S3Y4Tpc47DqA>? M1HlZ|I1QDF3MEi3
MDDCs NVn1RpJ{TnWwY4Tpc44hSXO|YYm= NHvHNIUxNTF3IN88US=> M{TmOVQ5KGh? NVTUcJhMTE2VTx?= M3XH[IlvcGmkaYTzJG1KWC1zYTygUWlRNTGkIHHu[EBTSU6WRWOgdJJw\HWldHnvci=> MkHWNlQ5OTVyOEe=
MDDCs NXf0[VB{TnWwY4Tpc44hSXO|YYm= MYKxNEDPxE1? MW[zMlUhcA>? MnnuSG1UVw>? NYP3ZXl1[myxY3vzJGVDV1ZiR2CsJIJ2fCCwb4SgWnNXKEdibXXkbYF1\WRiZX70dpkhcW62bzDoeY1idiCPRFTDdy=> NVuwRXY3OjR6MUWwPFc>
macrophages MWHGeY5kfGmxbjDBd5NigQ>? MnzyNgKBkc7:TR?= MV60MlXjiImq MW\jc41xdGW2ZXz5JIlvcGmkaYTzJG1VNUmLST3pcoR2[2WmIHHjeIl3[XSrb36gc4YhVkZvzsrC Mn:0NlQ5ODh4M{O=
PDL  Ml71SpVv[3Srb36gRZN{[Xl? MnflNlDDqM7:TdMg NUPzSmoyOzBibXnu Mne5SG1UVw>? MX\zbYdvcW[rY3HueIx6KGmwaHnibZR{KHSqZTD0[Y5{cWynIH\vdoNmNW2nZHnheIVlKEKPUD2yJIV5eHKnc4Ppc44> M2PsclI1PTZzMEix
AGS MXHGeY5kfGmxbjDBd5NigQ>? NUHrdI5nPSEQvF2= NFvLS3A{OCCvaX6= NHH2XWl{fXCycnXzd4V{yqBzLXnu[JVk\WRiY3HzdIF{\S16IHHu[EBk[XOyYYPlMVMh[WO2aY\heIlwdg>? NXK2bIFLOjR3NEe4O|g>
H520 MXHGeY5kfGmxbjDBd5NigQ>? MVixNOKhyrWP NI\zVnoyKGh? MXrEUXNQ MY\k[YNz\WG|ZYOgeIhmKHCnbXX0doV5\WRvaX7keYNm\CCPU1iyJI1TVkFiYX7kJJBzd3SnaX6gcIV3\Wy| Mn7UNlQ2OzB2N{W=
H1703 MYrGeY5kfGmxbjDBd5NigQ>? NIn1WG0yOMLiwsXN MVuxJIg> M4q3T2ROW09? M2HITIRm[3KnYYPld{B1cGVicHXt[ZRz\XinZD3pcoR2[2WmIF3TTFIhdVKQQTDhcoQheHKxdHXpckBt\X[nbIO= NGnGTo8zPDV|MES3OS=>
H520 MUXGeY5kfGmxbjDBd5NigQ>? NXvCUXJFOTEEoNM1US=> MXqxNkBp NVzBSm5lTE2VTx?= MYHpcohq[mm2czDw[Y1mfHKneHXkMYVtcWOrdHXkJG1UUDJicILveIVqdiC|dHHibYxqfHl? NUHrUVBQOjR3M{C0O|U>
H1703 MWDGeY5kfGmxbjDBd5NigQ>? MXKxNOKhyrWP Ml25NVIhcA>? NVm4eoIyTE2VTx?= M2H1N4lvcGmkaYTzJJBmdWW2cnX4[YQu\WyrY3n0[YQhVVOKMjDwdo91\WmwIIP0ZYJqdGm2eR?= MWGyOFU{ODR5NR?=
H520 MYnGeY5kfGmxbjDBd5NigQ>? Mnu3NVDDqML3TR?= M3eyOlYhcA>? MYXEUXNQ NUXxWGhOe2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgeIhmKGyndnXsd{Bw\iC3YnnxeYl1cW5vY3;ubpVo[XSnZDDNV2gzKGmwIIDlcYV1emW6ZXSteJJm[XSnZNMgZ4VtdCCuaX7l M4n2WVI1PTNyNEe1
H1703 M1XCRWZ2dmO2aX;uJGF{e2G7 NWezWIQ3OTEEoNM1US=> NYXwTGpJPiCq NEjLZXZFVVOR NXn4W3ZVe2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgeIhmKGyndnXsd{Bw\iC3YnnxeYl1cW5vY3;ubpVo[XSnZDDNV2gzKGmwIIDlcYV1emW6ZXSteJJm[XSnZNMgZ4VtdCCuaX7l MnuzNlQ2OzB2N{W=
MC3T3-E1 NGjzV2dHfW6ldHnvckBCe3OjeR?= M1;FbFAvOy9|L{OwJO69VQ>? MVOxJIg> MUDheJRmdnWjdHXzJHRPTi4QsT3pcoR2[2WmIF3NVE06KGW6cILld5Nqd25iaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XMEoB?= MkjQNlQ2ODJ4OU[=
MC3T3-E1 M4nFW2Z2dmO2aX;uJGF{e2G7 MYWzNEDPxE1? MYGxJIg> NF:5eHFifHSnboXheIV{KFSQRj5OtU1{fGmvdXzheIVlKHB|ODDNRXBMKHCqb4PwbI9zgWyjdHnvci=> NILWfoMzPDVyMk[5Oi=>
HUVECs  NVzKSYZTTnWwY4Tpc44hSXO|YYm= NUHITIhxOTEEoNM1US=> MkPaNUBp MnXFbY5pcWKrdIOgWG5HNc7zLXnu[JVk\WRiQ2jDUFEheHKxZIXjeIlwdg>? MYSyOFQ5Pzl4NB?=
AGS  NF3oN5NHfW6ldHnvckBCe3OjeR?= M1;DfVExyqEEtV2= Mm\0N|DDqG2rbh?= NVXhPHVkcW6qaXLpeJMhUUxvMd8yMYlv\HWlZXSgZYN1cX[jdHnvckBw\iCyM{i= MlfBNlQ1Pzl4OEG=
MKN-45 Mlu4SpVv[3Srb36gRZN{[Xl? M{fHeVExyqEEtV2= NFX4RVY{OMLibXnu Mkm4bY5pcWKrdIOgTWwuOc7{LXnu[JVk\WRiYXP0bZZifGmxbjDv[kBxOzh? M4L1S|I1PDd7Nkix
AGS  MYnGeY5kfGmxbjDBd5NigQ>? M1z2WVExyqEEtV2= NYjjWWlVOzEEoH3pci=> MXvheJRmdnWjdHXzJGlNNTIQsj3pcoR2[2WmIFfBJINmdGxibXnndoF1cW:wIHHu[EBqdn[jc3nvci=> MUOyOFQ4QTZ6MR?=
MKN-45 NEfRRZNHfW6ldHnvckBCe3OjeR?= M3rSZlExyqEEtV2= M2XJPFMxyqCvaX6= M4rhN4F1fGWwdXH0[ZMhUUxvMd8yMYlv\HWlZXSgS2Eh[2WubDDtbYdz[XSrb36gZY5lKGmwdnHzbY9v MlnVNlQ1Pzl4OEG=
AGS  NED5SppHfW6ldHnvckBCe3OjeR?= NFTydJEyOMLiwsXN MWWzNOKhdWmw M3;l[5Nq\26rZnnjZY51dHliZHXjdoVie2W|IFnsMVHPui2rbnT1Z4VlKE2PUEKgZY5lKE2PUEmgcXJPSSCneIDy[ZN{cW:w NGi0UJozPDR5OU[4NS=>
MKN-45 MWTGeY5kfGmxbjDBd5NigQ>? MU[xNOKhyrWP M1jMWlMxyqCvaX6= MVrzbYdvcW[rY3HueIx6KGSnY4LlZZNmeyCLbD2x{tIucW6mdXPl[EBOVVB{IHHu[EBOVVB7IH3SUmEh\XiycnXzd4lwdg>? MV:yOFQ4QTZ6MR?=
DCs MYrGeY5kfGmxbjDBd5NigQ>? NVz3enRlOjEEoN88US=> MWKxxsBp MVHk[YNz\WG|ZYOgTWwuOTJicILv[JVkfGmxbh?= MnTFNlQ1OzR4M{[=
HUVEC  MoT5SpVv[3Srb36gRZN{[Xl? NVX6fZdUOjBizsztxsA> NHizPWQ2KGh? NGSxcGhFVVOR NX71Vmp7emWmdXPld{BkgXSxa3nu[UBmgHC{ZYPzbY9vKGyndnXsd{BqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7ldi=> M4PCe|I1OTh7ME[y
A 549 Ml3TSpVv[3Srb36gRZN{[Xl? NETzeWs2OCEQvF2= NHzJO3gyKGh? MUnk[YNz\WG|ZYOgeIhmKGyndnXsJI9nKEmOLUlCpC=> M4jmc|I1OTd7Nki4
H520  NVfZVpBOTnWwY4Tpc44hSXO|YYm= M1v0VFUwOTBizszN MWmxJIg> NGKyfFlFVVOR Mknk[IVkemWjc3XzJG1UUDJicILveIVqdiCjczD3[YxtKGG|IH3SUmEhdGW4ZXzzJIlvKGenZnn0bY5q[i2neIDvd4VlKGOnbHy= M1TNO|I1OTN6OUCz
H1703  NYTBOGplTnWwY4Tpc44hSXO|YYm= NEDtZnI2NzFyIN88US=> NHrpUWIyKGh? MnXVSG1UVw>? M4K0UYRm[3KnYYPld{BOW0h{IIDyc5RmcW5iYYOge4VtdCCjczDtVm5CKGyndnXsd{BqdiCpZX\peIlvcWJvZYjwc5Nm\CClZXzs MkjkNlQyOzh7MEO=
H520  M4O4fGZ2dmO2aX;uJGF{e2G7 MXmxNOKhyrWP M1[1[lEzKGh? NITNVFFFVVOR NVHmfXFJ\GWlcnXhd4V{KE2VSEKgcXJPSSCjbnSgdJJwfGWrbjDzeIFjcWyrdImgbY4h\2WoaYTpcoljNXS{ZXH0[YQhVlOFTFOgZ4VtdHN? MU[yOFE{QDlyMx?=
H1703  NWjqPGg2TnWwY4Tpc44hSXO|YYm= MXmxNOKhyrWP NF;PbFIyOiCq NX;lbYhvTE2VTx?= M4D3d4Rm[3KnYYPld{BOW0h{IH3SUmEh[W6mIIDyc5RmcW5ic4ThZoltcXS7IHnuJIdm\mm2aX7pZk11emWjdHXkJG5US0yFIHPlcIx{ NGewZ|EzPDF|OEmwNy=>
MCF-7  MmW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\LVWdtOTEEoN88US=> MUCyOOKhcA>? MkjXbY5pcWKrdIOgeIhmKEOUMUC4MYlv\HWlZXSgZ4VtdCCmZXH0bC=> MnznNlQyOjh6NUO=
HPAEpiCs Mn62SpVv[3Srb36gRZN{[Xl? NX[1UVBROC5zL{GvNVAh|ryP MWWxJIg> NF[5cHNqdmirYnn0d{BVVkZvzsGtbY5lfWOnZDDjVGxCOsLicILveIVqdiCjbnSgcXJPSSCneIDy[ZN{cW:w NIfWTpIzPDB4OUG1PC=>
podocytes MVvGeY5kfGmxbjDBd5NigQ>? MV:xNOKh|ryP NInId|IyKGh? NGDkR41qdmirYnn0d{BVT0cQskGtbY5lfWOnZDDhZ5RqfmG2aX;uJI9nKHB|OF3BVGsh[W6mIFXyb|EwOsLi MVeyOFA{PjJzMh?=
MCF-7 NY\HVnJqTnWwY4Tpc44hSXO|YYm= M2DCS|ExyqEQvF2= MoDONUBp MlnLSG1UVw>? NXTGVYFjemWmdXPld{B1cGViV1GtbY5lfWOnZDDwbI9{eGixconsZZRm\CCyM{igUWFRUw>? M3Xte|I1ODF7MEmw
MCF-7 NWrPOVlETnWwY4Tpc44hSXO|YYm= M1zub|ExyqEQvF2= MYSyOEBp NH\wZY1FVVOR MmTibY5kemWjc3XzJJRp\SCZQT3pcoR2[2WmIHHwc5B1d3Orcx?= Mmf0NlQxOTlyOUC=
HAPI MVPGeY5kfGmxbjDBd5NigQ>? MUCxNE8zOC92MNMg{txO NEW1U|cyKGh? MnvmbY5pcWKrdIOgWGNFTC2rbnT1Z4VlKHB|OD;KUmshVUGSSzDwbI9{eGixconsZZRqd25? NWnXfJE6OjN7NkmxNlA>
HAPI MmnCSpVv[3Srb36gRZN{[Xl? NXHYZYVLOjEEoN88UeKh MYOxJIg> MV7EUXNQ MVfheJRmdnWjdHXzJHRETERvaX7keYNm\CCjY4TpeoF1cW:wIH;mJIlPV1NiYX7kJJBzd2S3Y4Tpc44> MVuyN|k3QTF{MB?=
HepG2 NXzGVJNPTnWwY4Tpc44hSXO|YYm= MmTYN|UxKG6P MYeyOEBp MVjpcohq[mm2czD0bIUh\GWpdXXsbY4ucW6mdXPl[EBi[3SrdnH0bY9vKG:oIICzPG1CWEt? NUDZ[XJGOjN7M{OxPVg>
AGS  NX\xT3FUTnWwY4Tpc44hSXO|YYm= NWHyXZdDOTEEoN88US=> MnfnN|AhdWmw M1jnTIlvcGmkaYTzJINie3Cjc3WtN{Bi[3SrdnH0bY9vKGGwZDDpcohq[mm2aX;uJI9nKEWUSx?= MmL3NlM5PTB7OUS=
HepG2 NG\V[YxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfnOnpkOC13MDFOwG0> NGLKSXU1QCCq NG\RPGpqdmirYnn0d{B1cGVicILvcIln\XKjdHnvckBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> MlHPNlM5ODd3MEi=
BEL7404 MorhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\CV5dsOC13MDFOwG0> NFPvb2Y1QCCq M{\LbYlvcGmkaYTzJJRp\SCycn;sbYZmemG2aX;uJIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy MYKyN|gxPzVyOB?=
HL7702 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnDS2hPOC13MDFOwG0> NYewUZl1PDhiaB?= MXHpcohq[mm2czD0bIUheHKxbHnm[ZJifGmxbjDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= M{LaSVI{QDB5NUC4
HepG2 MoXDSpVv[3Srb36gRZN{[Xl? NIr1dHIxNTVyIN88US=> MYOyOEBp NEX3W4JqdmirYnn0d{B1cGVicHjvd5Bpd3K7bHH0bY9vKG:oIICzPEBld3ewc4Ty[YFuKHC{b4TlbY5{KE2DUFvBVGszNCCDVF[yMEBOW0tzIHHu[EBJW1B{NzDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M4Pne|I{QDB5NUC4
BEAS-2B NGnYNppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDRNnIyOCEQvF2= M3TrN|MxKG2rbh?= NH7nbotz\X[ncoPld{B1cGViZHXjdoVie2Vib3[gZ4VtdCC4aXHibYxqfHliaX7keYNm\CCkeTDIR2k> NYPLepdEOjN5OESwN|Q>
BEAS-2B M4PV[WN6fG:2b4jpeJkhSXO|YYm= NWq3dXd3OTBizszN NV\iZpg4OzBibXnu MWPpcohq[mm2ZXSgeIhmKGmwY4LlZZNmKGmwIFzETEBidmRiSVytPEBmgHC{ZYPzbY9v MX2yN|c5PDB|NB?=
BEAS-2B MWTGeY5kfGmxbjDBd5NigQ>? NXvSO25XOTBizszN NWXJUZk{OzBibXnu MlS5[IVkemWjc3XzJJRp\SCuZY\lcJMhd2ZiY3HzdIF{\S1|LDDCZYQh[W6mIH\hdy=> M{nlbFI{Pzh2MEO0
H9c2  MVvGeY5kfGmxbjDBd5NigQ>? NWX1XWpUOC5yMT:wMlEwOSEQvF2= MY[xJIg> NWj2bHp6[XS2ZX71ZZRmeyCWTl[t{tEucW6mdXPl[EBOVVBvOTDlfJBz\XO|aX;uMEBuWk6DIHzleoVteyxiYX7kJJBzd22xdHXyJIFkfGm4aYT5 MVqyN|c4PDJ3Mh?=
H9c2  MkezSpVv[3Srb36gRZN{[Xl? MYOxJO69VQ>? NFHDWXcyKGh? NFHpO4Zz\WS3Y3XzJHRPTi4QsTDkbZJm[3SueTDzeIlufWyjdHXkJJA{QCCPQWDLJJBpd3OyaH;yfYxifGmxbh?= MmX6NlM4PzR{NUK=
U937 NFXQVlNHfW6ldHnvckBCe3OjeR?= M4fJZVExyqEQvF5CpC=> NGHPVFcyKGh? NH3DWm1i[nKxZ3H0[ZMhfGinIHPh[oZmcW6nIHXm[oVkfCCxbjDNT3AuOSCjbnSgVHAzSWQQsTDtVm5CKHS{YX7zZ5JqeHSrb37hcEBt\X[nbIO= MY[yN|cxPzN6Nx?=
U937 MmrLSpVv[3Srb36gRZN{[Xl? M4TvNFExyqEQvF5CpC=> NGjlOpEyKGh? NUf2VWxE[WK{b3fheIV{KGOjZn\lbY5mNWmwZIXj[YQhVUuSLUGg[I94di2{ZXf1cIF1cW:wIHHu[EBRWDKDY98xJJVxNXKnZ4XsZZRqd25? MWCyN|cxPzN6Nx?=
U937 MVnGeY5kfGmxbjDBd5NigQ>? NX3wVYVpOTEEoN88UeKh NEnS[pAyKGh? NV;yWGhRe3WycILld5NmeyClLVr1ckBidmRiQ2LFRkBxcG:|cHjvdplt[XSrb36gbY4h[2GoZnXpcoUufHKnYYTl[EBk\Wyuc9Mg MkHKNlM4ODd|OEe=
A549 NVjlTGRrTnWwY4Tpc44hSXO|YYm= MWewMlMwOy9|MDFOwG0> MXyxJIg> NHvDbJp{cWewaX\pZ4FvfGy7IHH0eIVvfWG2ZYOgRXRR|rOVLX3l[IlifGWmIFPPXE0zKHC{b4TlbY4h[W6mIH3SUmEh\XiycnXzd4lwdiCjbnSgdJJwdW:2ZYKgZYN1cX[rdIpCpC=> MX6yN|Y5ODZ5NB?=
A549 NYjy[GZpTnWwY4Tpc44hSXO|YYm= NUnHUWVQOTEEoN88UeKh NFy5OpcxNTNyIH3pci=> MX7pcohq[mm2czDBWHDPu1NiaX7keYNm\CCyNEKvdFQ1KE2DUFugZY5lKHB|ODDNRXBMKHCqb4PwbI9zgWyjdHnvci=> M1LSRVI{PjhyNke0
A549 M{nWNWZ2dmO2aX;uJGF{e2G7 M2rVOVExyqEQvF5CpC=> M4HnZ|EhcA>? NIfBVWNqdmirYnn0d{BCXFEQs2OgbY5lfWOnZDDOSk3PwkJicE[1JJN2[nWwaYSgdIhwe3Cqb4L5cIF1cW:wIHHu[EBPTi4QulKgdJJwdW:2ZYKgZYN1cX[rdIm= M16ydlI{PjhyNke0
A549 MVnGeY5kfGmxbjDBd5NigQ>? NHLKSWQyOMLizszNxsA> M1i2OlEhcA>? NXjrcnVJemWmdXPld{BCXFEQs2Otd5RqdXWuYYTl[EBkWEyDMjDwbI9{eGixconsZZRqd28EoB?= MYiyN|Y5ODZ5NB?=
A549 M1HOZ2Z2dmO2aX;uJGF{e2G7 M3;Qc|ExyqEQvF5CpC=> MX6xJIg> MXny[YR2[2W|IFHUVO6{Wy2nbnjhcoNm\CCnbor5cYF1cWNiYXP0bZZqfHlib3[gZ3BNSTMEoB?= NXizSpVxOjN4OEC2O|Q>
PC12 NVfj[45yTnWwY4Tpc44hSXO|YYm= NWTzPYNHOTBxMkCvOFAh|ryP M3v6blHDqGh? NHrPPWdqdmirYnn0d{BLVktiYX7kJJA{QA>? MWSyN|U5PDN3Nx?=
HK-2 MkW4RZBweHSxc3nzJGF{e2G7 MWiyNOKh|ryP NEn4OYMzPCCq NFGz[|VqdmirYnn0d{BGWktiYX7kJJA{QE2DUFu= MWKyN|U1OzF3MR?=
H9c2 M{jRUGZ2dmO2aX;uJGF{e2G7 NUTBTJZnOcLizszN NWrld5V3OSCq MVfy[YR2[2W|IGTOSk3PuS2rbnT1Z4VlKE2PUD25JI1TVkFibHX2[Yx{KGGwZDDwdo9ud3SncjDhZ5Rqfmm2eR?= NEX3WVgzOzN3M{[5PS=>
H9c2 MnrVSpVv[3Srb36gRZN{[Xl? NHHCTVkyyqEQvF2= MVyxJIg> NFfRR|Jz\WS3Y3XzJHRPTi4QsT3lcohidmOnZDDBVE0yKHC{b33veIVzKGGldHn2bZR6 M2LVNlI{OzV|Nkm5
H1650  Ml\pSpVv[3Srb36gRZN{[Xl? MlrMNVDDqM7:TdMg Ml7XNUBp MVzEUXNQ NXztTJdH\GWlcnXhd4V{KGKxdHigdJJwfGWrbjDhcoQhdVKQQTDs[ZZmdHNib3[gSXJESzFiaX6gdIFkdGm2YYjlcE1mgHCxc3XkxsBk\Wyucx?= NWOzT5B5OjN{Mki2PVY>
H1703 NHPuUZdHfW6ldHnvckBCe3OjeR?= M{HDeVExyqEQvF5CpC=> M{fEPVEhcA>? M1HxS2ROW09? Mm\y[IVkemWjc3XzJIJwfGhicILveIVqdiCjbnSgcXJPSSCuZY\lcJMhd2ZiRWLDR|EhcW5icHHjcIl1[XinbD3lfJBwe2WmwrDj[Yxtew>? M4L2c|I{OjJ6Nkm2
H1650  Mn63S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvPNVDDqM7:TdMg NV31e5p4OSCq M2DLOWROW09? MkTW[Y5p[W6lZYOgdIFkdGm2YYjlcE1qdmS3Y3XkJIN6fG:2b4jpZ4l1gQ>? NFLOVW4zOzJ{OE[5Oi=>
H1703 M1fYSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HnN|ExyqEQvF5CpC=> M3z6[VEhcA>? MUTEUXNQ Ml\C[Y5p[W6lZYOgdIFkdGm2YYjlcE1qdmS3Y3XkJIN6fG:2b4jpZ4l1gQ>? MXWyN|IzQDZ7Nh?=

... Click to View More Cell Line Experimental Data

In vivo Inhibiting p38 by administration of SB 202190 inhibits PV IgG-induced blister formation in the passive transfer mouse model. [5] In the endotoxin model of sepsis, SB 202190 treatment produces a statistically significant survival benefit compared with control. [8]

Protocol

Kinase Assay:

[1]

+ Expand

In vitro kinase assays:

The p38α and p38β are assayed in 25 mM Tris-HCl, pH 7.5, containing 0.1 mM EGTA, with myelin basic protein (0.33 mg/mL) as substrate. Assays are performed either manually for 10 minutes at 30 °C in 50 μL incubations using [γ-33P]ATP, or with a Biomek 2000 Laboratory Automation Workstation in a 96-well format for 40 minutes at ambient temperature in 25 μL incubations using [γ-33P]ATP. The concentrations of ATP and magnesium acetate are 0.1 mM and 10 mM respectively. All assays are initiated with MgATP. Manual assays are terminated by spotting aliquots of incubation on to phosphocellulose paper, followed by immersion in 50 mM phosphoric acid. Robotic assays are terminated by the addition of 5 μL of 0.5 M phosphoric acid before spotting aliquots on to P30 filter mats. All papers are then washed four times in 50 mM phosphoric acid to remove ATP, once in acetone (manual incubations) or methanol (robotic incubations), and then dried and counted for radioactivity.
Cell Research:

[2]

+ Expand
  • Cell lines: Jurkat, and HeLa
  • Concentrations: Dissolved in DMSO, final concentrations ~50 μM
  • Incubation Time: 24 hours
  • Method:

    Cells are serum-starved and then treated with different concentration of SB 202190 for 24 hours. Cell viability is assayed by either trypan blue exclusion or propidium iodide exclusion followed by flow cytometry analysis. The apoptotic nuclei are visualized by H33258 staining.


    (Only for Reference)
Animal Research:

[5]

+ Expand
  • Animal Models: C57BL/6J mice injected i.d. with a sterile solution of either control IgG or PV IgG
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: 12.5 μg
  • Administration: Administered via i.d.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 66 mg/mL (199.19 mM)
Ethanol 12 mg/mL (36.21 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
1% DMSO+30% polyethylene glycol+1% Tween 80
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 331.34
Formula

C20H14N3OF

CAS No. 152121-30-7
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

p38 MAPK Signaling Pathway Map

p38 MAPK Inhibitors with Unique Features

Related p38 MAPK Products

Tags: buy SB202190 (FHPI) | SB202190 (FHPI) supplier | purchase SB202190 (FHPI) | SB202190 (FHPI) cost | SB202190 (FHPI) manufacturer | order SB202190 (FHPI) | SB202190 (FHPI) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID